Dynamic Technology Lab Private Ltd Invests $1.13 Million in Catalent, Inc. (NYSE:CTLT)

Dynamic Technology Lab Private Ltd bought a new stake in shares of Catalent, Inc. (NYSE:CTLT) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 18,665 shares of the company’s stock, valued at approximately $1,131,000.

Other institutional investors also recently bought and sold shares of the company. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Catalent by 3.7% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company’s stock valued at $24,550,000 after acquiring an additional 14,373 shares in the last quarter. Quest Partners LLC grew its position in shares of Catalent by 289.8% in the 3rd quarter. Quest Partners LLC now owns 49,300 shares of the company’s stock worth $2,986,000 after buying an additional 36,652 shares during the period. Swedbank AB purchased a new stake in Catalent in the first quarter worth about $1,659,000. New York Life Investment Management LLC increased its stake in shares of Catalent by 67.9% during the second quarter. New York Life Investment Management LLC now owns 297,903 shares of the company’s stock valued at $16,751,000 after purchasing an additional 120,502 shares in the last quarter. Finally, Van ECK Associates Corp lifted its holdings in shares of Catalent by 47.4% during the third quarter. Van ECK Associates Corp now owns 124,424 shares of the company’s stock valued at $7,391,000 after purchasing an additional 39,983 shares during the last quarter.

Insiders Place Their Bets

In other news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the transaction, the director now owns 10,835 shares in the company, valued at $646,849.50. This trade represents a 20.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,114 shares of company stock valued at $305,931. Insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on CTLT shares. William Blair reiterated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Robert W. Baird reissued a “neutral” rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. Finally, StockNews.com cut shares of Catalent from a “hold” rating to a “sell” rating in a report on Friday, November 22nd. One equities research analyst has rated the stock with a sell rating and seven have given a hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $63.40.

Catalent Stock Performance

Shares of CTLT stock opened at $60.76 on Wednesday. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The company has a 50 day moving average price of $59.83 and a 200-day moving average price of $58.36. Catalent, Inc. has a 52 week low of $36.74 and a 52 week high of $61.50. The firm has a market capitalization of $11.03 billion, a PE ratio of -26.88, a P/E/G ratio of 2.42 and a beta of 1.16.

Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. Catalent’s quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.10) earnings per share. As a group, equities research analysts expect that Catalent, Inc. will post 0.84 earnings per share for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.